Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the consequences of amyloid protein polymorphism in regulation and initiation of early pathogenesis in Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of biochemical and cellular pathways that are responsible for the differential accumulation of various protein conformers in AD clinical subtypes.

The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells are essential to understanding the etiology of AD.

As part of this mission, the foundation is seeking applications for scientific research projects with the potential to significantly advance the field toward an effective understanding of the mechanisms of cerebrovascular disease. TAAF grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management, and recovery for patients.

The intent of the FY19 PRARP CSRA is to support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences related to the PRARP's mission (see Section II.A, Program Description). The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the PRARP's mission and vision. The research innovations for the FY19 PRARP CSRA are expected to benefit the military, Veteran, and civilian communities. FY19 PRARP CSRA applications should be Innovation- and Impact-based.

The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.

This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA-supported Alzheimer's Disease Research Centers (ADRCs). An additional activity will be to define appropriate imaging protocols, as well as assess and anticipate advances in neuroimaging technologies and techniques for inclusion in the standardized protocols to maximize utility for the field of Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) research.

This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.

Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission

To that end, the organization is currently accepting applications for its Harry Weaver Neuroscience Scholar Award, which is named for Harry Weaver, PhD, known worldwide for his contribution to Neuroscience and multiple sclerosis research and the society's director of research from 1966-1977. Over the course of his tenure and career, Weaver encouraged young investigators to enter and pursue MS research and broaden understanding of basic and clinical aspects of multiple sclerosis.

Fluctuations in mental status occur commonly in dementia. Such fluctuations vary by dementia type and are most apparent in earlier stages of disease. However, even in late-stage dementia, patients have been reported to exhibit unexpected episodes of mental clarity or lucidity, characterized by spontaneous meaningful and relevant communication at a time when the capacity for coherent speech has presumably been lost.

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH.

This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.

The National Multiple Sclerosis Society believes in a world free of MS and is dedicated to ensuring that people affected by MS can live their best lives. To that end, the organization is currently accepting applications for its Harry Weaver Neuroscience Scholar Award, which is named for Harry Weaver, PhD, known worldwide for his contribution to Neuroscience and multiple sclerosis research and the society's director of research from 1966-1977. Over the course of his tenure and career, Weaver encouraged young investigators to enter and pursue MS research and broaden understanding of basic and clinical aspects of multiple sclerosis. Through the program, five-year grants in support of salary and research will be awarded to highly-qualified candidates who have concluded their research training and begun their academic careers as an independent investigator in an area related to multiple sclerosis. Up to 75 percent of annual salary support may be requested, not to exceed $75,000 in year one, as well as up to $30,000 for research-associated direct costs, with incremental increases possible in each of the remaining four years.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multi-disciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in individuals with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention. 

This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for skills development, particularly short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.

This funding opportunity will support a new, centralized infrastructure (U24) to aggregate, harmonize, manage, and share existing and future neuroimaging data collected in NIA- supported Alzheimer's Disease Research Centers (ADRCs).

This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's Disease (AD) and AD Related Dementias (ADRD) in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.

The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.

 The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this NIDA/NIMH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on  Courses for Skills Development. In particular, NIDA/NIMH are interested in supporting short-term workshops that will allow participants to explore the hands-on use of ABCD data, through cooperative or competitive approaches.